| Year |
Citation |
Score |
| 2020 |
Weidhaas JB. Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. Methods in Molecular Biology (Clifton, N.J.). 2055: 203-212. PMID 31502153 DOI: 10.1007/978-1-4939-9773-2_9 |
0.367 |
|
| 2019 |
Jung SY, Malhotra P, Nguyen KC, Salzman D, Qi Y, Pak EH, King J, Vlashi E, Ann D, Weidhaas JB. The KRAS-variant and its impact on normal breast epithelial cell biology. Cell Death and Differentiation. PMID 30932013 DOI: 10.1038/S41418-019-0320-Y |
0.802 |
|
| 2019 |
Malhotra P, Read GH, Weidhaas JB. Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. Non-Coding Rna. 5. PMID 30897768 DOI: 10.3390/ncrna5010027 |
0.432 |
|
| 2019 |
Yuan Y, Weidhaas JB. Functional microRNA binding site variants. Molecular Oncology. 13: 4-8. PMID 30536617 DOI: 10.1002/1878-0261.12421 |
0.312 |
|
| 2019 |
Weidhaas JB, Scheffler AW, Salzman D, Kalbasi A, Wilenius K, Rietdorf E, Heilig M, Pitka M, Desler C, Ruan D, Ribas A, Drakaki A, Scholz MC, Telesca D. A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy. Journal of Clinical Oncology. 37: 96-96. DOI: 10.1200/Jco.2019.37.8_Suppl.96 |
0.74 |
|
| 2018 |
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Richter CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA Signatures Discriminate Between Uterine and Ovarian Serous Carcinomas. Human Pathology. PMID 29518404 DOI: 10.1016/j.humpath.2018.02.019 |
0.321 |
|
| 2018 |
Weidhaas JB, Wilenius K, Scheffler AW, Higa J, Telesca D, Scholz MC. A microRNA-based signature predicting immune-related toxicity (iRAEs) to pembrolizumab in prostate cancer patients. Journal of Clinical Oncology. 36: 269-269. DOI: 10.1200/Jco.2018.36.6_Suppl.269 |
0.329 |
|
| 2017 |
Mehta AK, Hua K, Whipple W, Nguyen MT, Liu CT, Haybaeck J, Weidhaas J, Settleman J, Singh A. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Science Signaling. 10. PMID 28900044 DOI: 10.1126/scisignal.aam6291 |
0.342 |
|
| 2017 |
McVeigh TP, Mulligan RJ, McVeigh UM, Owens PW, Miller N, Bell M, Sebag F, Guerin C, Quill D, Weidhaas JB, Kerin M, Lowery AJ. Investigating the association of rs2910164 with cancer in Irish patients. Endocrine Connections. PMID 28899898 DOI: 10.1530/EC-17-0196 |
0.317 |
|
| 2017 |
Weidhaas JB, Telesca D, Kalbasi A, Salzman D, Ribas A. Germ-line biomarkers disrupting microRNA regulatory pathways to predict toxicity and response to anti-PD-1 and anti-PD-L1 therapies. Journal of Clinical Oncology. 35: 3040-3040. DOI: 10.1200/Jco.2017.35.15_Suppl.3040 |
0.761 |
|
| 2016 |
Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9. Non-Coding Rna. 2. PMID 29657269 DOI: 10.3390/Ncrna2040010 |
0.697 |
|
| 2016 |
Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding Rna. 2. PMID 29657267 DOI: 10.3390/Ncrna2030009 |
0.698 |
|
| 2016 |
Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas J, Tuck DP, Sweasy JB. Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-associated R438W DNA Polymerase Lambda Protein. Molecular Cancer Research : McR. PMID 27621267 DOI: 10.1158/1541-7786.Mcr-16-0209 |
0.301 |
|
| 2016 |
Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ. cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. Oncogene. PMID 27321180 DOI: 10.1038/Onc.2016.222 |
0.541 |
|
| 2016 |
Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB. miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. Nature Communications. 7: 10954. PMID 26996824 DOI: 10.1038/Ncomms10954 |
0.77 |
|
| 2015 |
McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, ... ... Weidhaas JB, et al. Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle (Georgetown, Tex.). 14: 2091-9. PMID 25961464 DOI: 10.1080/15384101.2015.1041694 |
0.787 |
|
| 2015 |
Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ. Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene. 34: 2125-37. PMID 24909162 DOI: 10.1038/Onc.2014.117 |
0.608 |
|
| 2015 |
Weidhaas JB, McVeigh TP, Jung SY, Salzman D, Nallur S, Dookwah M, Nemec AA, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, et al. Estrogen withdrawal, breast cell transformation, and multiple breast cancer risk in women with the KRAS-variant. Journal of Clinical Oncology. 33: e12541-e12541. DOI: 10.1200/Jco.2015.33.15_Suppl.E12541 |
0.772 |
|
| 2015 |
Weidhaas JB, Mcveigh T, Pilarski R, Miller N, Sweasy J, Kerin M, Nallur S, Sadofsky J, Nemec A, Sweeney K, Daniel Z. Abstract P6-10-02: The KRAS-variant, multiple breast cancer risk, and estrogen withdrawal Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-10-02 |
0.37 |
|
| 2014 |
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4499-510. PMID 25183481 DOI: 10.1158/1078-0432.CCR-14-0348 |
0.769 |
|
| 2014 |
Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, ... Weidhaas JB, et al. A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. Bmc Cancer. 14: 421. PMID 24915755 DOI: 10.1186/1471-2407-14-421 |
0.775 |
|
| 2014 |
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, ... ... Weidhaas J, et al. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. Plos One. 9: e94167. PMID 24732316 DOI: 10.1371/Journal.Pone.0094167 |
0.422 |
|
| 2014 |
Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle (Georgetown, Tex.). 13: 1030-40. PMID 24552817 DOI: 10.4161/Cc.27941 |
0.656 |
|
| 2014 |
Weidhaas JB, Kim ES, Herbst RS, Yu J, Slack F, Blumenschein GR, Tsao AS, Wistuba II, Lee JJ, Papadimitrakopoulou V, Hong WK, Heymach J, Tran HT. The KRAS-variant and treatment response in BATTLE-1. Journal of Clinical Oncology. 32: 8135-8135. DOI: 10.1200/Jco.2014.32.15_Suppl.8135 |
0.537 |
|
| 2014 |
Weidhaas JB, Harris J, Axelrod R, El-Naggar AK, Singh A, Galloway T, Raben D, Wang D, Herman TS, Lee RJ, Manon RR, Yumen O, Zhang Q, Chung CH. The KRAS-variant and cetuximab response in RTOG 0522. Journal of Clinical Oncology. 32: 6000-6000. DOI: 10.1200/Jco.2014.32.15_Suppl.6000 |
0.393 |
|
| 2013 |
Preskill C, Weidhaas JB. SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Critical Reviews in Oncogenesis. 18: 327-40. PMID 23614619 DOI: 10.1615/critrevoncog.2013007254 |
0.435 |
|
| 2013 |
Salzman DW, Weidhaas JB. SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacology & Therapeutics. 137: 55-63. PMID 22964086 DOI: 10.1016/j.pharmthera.2012.08.016 |
0.783 |
|
| 2013 |
Howard JD, Cheng H, Ratner E, Fertig EJ, Perez J, Quon H, Considine M, Ochs M, Weidhaas J, Chung CH. Abstract 3100: MicroRNA profiling reveals miR-205 upregulation is associated with head and neck squamous cell carcinoma and modulates E2F1 signaling. Cancer Research. 73: 3100-3100. DOI: 10.1158/1538-7445.Am2013-3100 |
0.306 |
|
| 2012 |
Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 109: E1695-704. PMID 22685206 DOI: 10.1073/Pnas.1201516109 |
0.512 |
|
| 2012 |
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. Plos One. 7: e37891. PMID 22662244 DOI: 10.1371/Journal.Pone.0037891 |
0.384 |
|
| 2012 |
Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle (Georgetown, Tex.). 11: 361-6. PMID 22189714 DOI: 10.4161/Cc.11.2.18794 |
0.66 |
|
| 2012 |
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, ... ... Weidhaas JB, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31: 4559-66. PMID 22139083 DOI: 10.1038/Onc.2011.539 |
0.626 |
|
| 2012 |
Kunos C, Winter K, Dicker A, Small W, Abdul-Karim F, Dawson D, Jhingran A, Valicenti R, Weidhaas J, Gaffney D. RTOG 0116 and 0128: Secondary analysis of ribonucleotide reductase in cervix cancer Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.104 |
0.311 |
|
| 2011 |
Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology & Therapy. 12: 908-14. PMID 22027557 DOI: 10.4161/Cbt.12.10.17681 |
0.555 |
|
| 2011 |
Weidhaas JB, Slack FJ. KRAS rs61764370 in Epithelial Ovarian Cancer-Letter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6600; author reply 6. PMID 22003074 DOI: 10.1158/1078-0432.Ccr-11-1195 |
0.57 |
|
| 2011 |
Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7723-31. PMID 21994416 DOI: 10.1158/1078-0432.CCR-11-0990 |
0.303 |
|
| 2011 |
Salzman DW, Weidhaas JB. miRNAs in the spotlight: Making 'silent' mutations speak up. Nature Medicine. 17: 934-5. PMID 21818091 DOI: 10.1038/nm0811-934 |
0.75 |
|
| 2011 |
Leaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, Zhu Y. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. International Journal of Molecular Epidemiology and Genetics. 2: 9-18. PMID 21552306 |
0.417 |
|
| 2011 |
Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (Georgetown, Tex.). 10: 1845-52. PMID 21543894 DOI: 10.4161/Cc.10.11.15777 |
0.588 |
|
| 2011 |
Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, ... ... Weidhaas J, et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. The Lancet. Oncology. 12: 377-86. PMID 21435948 DOI: 10.1016/S1470-2045(11)70044-4 |
0.648 |
|
| 2011 |
Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1116-22. PMID 21427705 DOI: 10.1038/Mt.2011.48 |
0.584 |
|
| 2011 |
Chan E, Prado DE, Weidhaas JB. Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends in Molecular Medicine. 17: 235-43. PMID 21354374 DOI: 10.1016/j.molmed.2011.01.008 |
0.41 |
|
| 2011 |
Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle (Georgetown, Tex.). 10: 90-9. PMID 21191178 DOI: 10.4161/Cc.10.1.14359 |
0.623 |
|
| 2011 |
Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, ... Weidhaas JB, et al. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene. 30: 1542-50. PMID 21119596 DOI: 10.1038/Onc.2010.536 |
0.605 |
|
| 2011 |
Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Research and Treatment. 128: 79-84. PMID 20676756 DOI: 10.1007/S10549-010-1080-Z |
0.377 |
|
| 2011 |
Weidhaas J, Slack F, Miller N, Harris L, Tuck D, Zhu Y, Zelterman D, Kerin M, Paranjape T, Heneghan H, Lindner R, Keane F, Dorairaj J, Geyda K, Pelletier C, et al. Association between KRAS rs61764370 and triple-negative breast cancer-a false positive? - Authors' reply The Lancet Oncology. 12: 724. DOI: 10.1016/S1470-2045(11)70163-2 |
0.554 |
|
| 2011 |
Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer (Gynecologic Oncology (2011) 120, (S3)) Gynecologic Oncology. 122: 205. DOI: 10.1016/J.Ygyno.2011.03.028 |
0.539 |
|
| 2011 |
Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer Gynecologic Oncology. 120: S3. DOI: 10.1016/J.Ygyno.2010.12.010 |
0.516 |
|
| 2010 |
Blitzblau RC, Weidhaas JB. MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. Molecular Diagnosis & Therapy. 14: 335-42. PMID 21275451 DOI: 10.1007/BF03256390 |
0.432 |
|
| 2010 |
Pelletier C, Weidhaas JB. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Review of Molecular Diagnostics. 10: 817-29. PMID 20843204 DOI: 10.1586/Erm.10.59 |
0.415 |
|
| 2010 |
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, ... ... Weidhaas JB, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Research. 70: 6509-15. PMID 20647319 DOI: 10.1158/0008-5472.Can-10-0689 |
0.624 |
|
| 2010 |
Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecologic Oncology. 118: 251-7. PMID 20542546 DOI: 10.1016/j.ygyno.2010.05.010 |
0.352 |
|
| 2010 |
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 29: 1580-7. PMID 19966857 DOI: 10.1038/Onc.2009.445 |
0.581 |
|
| 2010 |
Weidhaas JB. A KRAS-variant as a biomarker of ovarian cancer risk. Journal of Clinical Oncology. 28: 5016-5016. DOI: 10.1200/JCO.2010.28.15_SUPPL.5016 |
0.337 |
|
| 2010 |
Paranjape TS, Heneghan H, Pelletier C, Hoffman A, Kerin MJ, Harris L, Zhu Y, Miller N, Zelterman D, Tuck D, Slack F, Weidhaas J. Abstract 3029: A KRAS microRNA binding site polymorphism as a novel biomarker of risk in triple negative breast cancer Cancer Research. 70: 3029-3029. DOI: 10.1158/1538-7445.Am10-3029 |
0.641 |
|
| 2010 |
Weidhaas JB, Slack F. Abstract 1856: A KRAS-variant as a putative biomarker of ovarian cancer risk Cancer Research. 70: 1856-1856. DOI: 10.1158/1538-7445.Am10-1856 |
0.612 |
|
| 2010 |
Heneghan H, Miller N, Paranjape T, Slack F, Weidhaas J, Kerin M. O-43 A KRAS microRNA binding site variant is a genetic marker of risk for triple negative breast cancer European Journal of Cancer Supplements. 8: 16. DOI: 10.1016/J.Ejcsup.2010.06.044 |
0.565 |
|
| 2009 |
Elkin EB, Gonzales AR, Ishill NM, Klem ML, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Yahalom J. Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 607. PMID 27961468 DOI: 10.1200/Jco.2009.27.15_Suppl.607 |
0.329 |
|
| 2009 |
Weidhaas J. Using microRNAs to understand cancer biology. The Lancet. Oncology. 11: 106-7. PMID 20022811 DOI: 10.1016/S1470-2045(09)70386-9 |
0.392 |
|
| 2009 |
Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: Tools for cancer diagnostics Gut. 58: 1546-1554. PMID 19834118 DOI: 10.1136/Gut.2009.179531 |
0.633 |
|
| 2009 |
Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Research. 69: 5970-7. PMID 19567675 DOI: 10.1158/0008-5472.Can-09-0236 |
0.625 |
|
| 2009 |
Kato M, Paranjape T, Müller RU, Ullrich R, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 28: 2419-24. PMID 19421141 DOI: 10.1038/Onc.2009.106 |
0.594 |
|
| 2009 |
Paranjape T, Nallur S, Keanie K, Martel M, Haffty B, Tuck D, Slack F, Weidhaas J. MicroRNA profiling of triple negative breast cancer: predicting outcome and targets. Cancer Research. 69: 2040. DOI: 10.1158/0008-5472.Sabcs-2040 |
0.574 |
|
| 2009 |
Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. Erratum: The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells Oncogene. 28: 3008-3008. DOI: 10.1038/onc.2009.218 |
0.309 |
|
| 2008 |
Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics Oncogene. 27. PMID 19956180 DOI: 10.1038/Onc.2009.353 |
0.623 |
|
| 2008 |
Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. The New England Journal of Medicine. 359: 2720-2. PMID 19092157 DOI: 10.1056/Nejme0808667 |
0.61 |
|
| 2008 |
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, ... ... Weidhaas JB, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Research. 68: 8535-40. PMID 18922928 DOI: 10.1158/0008-5472.Can-08-2129 |
0.605 |
|
| 2008 |
Babar IA, Slack FJ, Weidhaas JB. miRNA modulation of the cellular stress response. Future Oncology (London, England). 4: 289-98. PMID 18407740 DOI: 10.2217/14796694.4.2.289 |
0.559 |
|
| 2008 |
Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (Georgetown, Tex.). 7: 759-64. PMID 18344688 DOI: 10.4161/Cc.7.6.5834 |
0.571 |
|
| 2007 |
Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Research. 67: 11111-6. PMID 18056433 DOI: 10.1158/0008-5472.Can-07-2858 |
0.619 |
|
| 2007 |
Weidhaas J, Slack F, Babar I, Nallur S. Using MicroRNAs to Alter the Radiation Response International Journal of Radiation Oncology*Biology*Physics. 69: S145-S146. DOI: 10.1016/J.Ijrobp.2007.07.266 |
0.465 |
|
| 2006 |
Slack FJ, Weidhaas JB. MicroRNAs as a potential magic bullet in cancer. Future Oncology (London, England). 2: 73-82. PMID 16556074 DOI: 10.2217/14796694.2.1.73 |
0.643 |
|
| Show low-probability matches. |